New Orleans, June 21-24, 2025 – Sichuan Longevous Beamtech Co.,Ltd (LBT) participated in the 72nd Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. The event attracted over 3,000 professionals including physicians, physicists, and researchers from 220+ enterprises across 50+ countries.
"Under the theme 'Accelerating The Cure', this year's conference focused on advanced topics including radiopharmaceutical development and molecular imaging technologies. Through keynote speeches, technical sessions, and research presentations, participating experts shared the latest research outcomes and clinical experience, infusing new momentum into the development of nuclear medicine and molecular imaging."
As an emerging force in the global medical cyclotron sector, LBT entered the North American market for the first time. At the conference, LBT attracted numerous international professionals to engage with its China-originated integrated radioisotope production solution. This solution combines advanced medical cyclotron equipment, radiopharmaceutical preparation technology, and full-process quality control systems, demonstrating China's technical capabilities in nuclear medicine equipment while providing global medical institutions, research centers, and related enterprises with a new efficient and safe isotope production alternative, positioned as a Chinese technological highlight at this conference.
During the exhibition, growing interest in LBT's booth attracted partners and professionals worldwide. Prospective clients from Australia, New Zealand, France, Japan and other countries held in-depth technical discussions with LBT's team on radioisotope production processes and equipment optimization. Partners from Mexico, Peru and other South American countries jointly planned next-stage collaborative development strategies. Additionally, Asian clients from Thailand, India and other regions conducted multiple rounds of consultations with LBT regarding localized service systems and joint R&D initiatives, actively exploring concrete cooperation plans.
As the host country, the U.S. market showed significant attention toward LBT. Multiple local hospitals, research institutions, and commercial clients demonstrated strong interest in the self-developed cyclotron system's efficient isotope production capability, intelligent interface, and comprehensive safety features, with some expressing clear collaboration intent. Notably, numerous Chinese-American nuclear medicine physicians, postdoctoral researchers, and lab technicians experienced LBT's Chinese-developed and manufactured cyclotrons at close range for the first time. They expressed excitement and pride at seeing domestically-produced high-end medical equipment on the international stage, anticipating greater contributions of 'Chinese technological excellence' to global nuclear medicine development.
LBT's globalization journey entered a new phase through this North American participation, successfully expanding its global footprint. The company will leverage this debut as a starting point to advance technological innovation and service optimization, steadily progressing toward its vision of becoming a 'world-leading nuclear medicine enterprise' to enhance the presence of Chinese technological excellence on the global nuclear medicine platform.
